Los Angeles Capital Management LLC Purchases New Position in ChromaDex Co. (NASDAQ:CDXC)

Los Angeles Capital Management LLC purchased a new stake in shares of ChromaDex Co. (NASDAQ:CDXC) in the 4th quarter, Holdings Channel reports. The fund purchased 218,528 shares of the company’s stock, valued at approximately $1,159,000.

Several other institutional investors have also recently added to or reduced their stakes in CDXC. BSW Wealth Partners bought a new position in ChromaDex during the 3rd quarter valued at about $324,000. BNP Paribas Financial Markets lifted its holdings in ChromaDex by 1,885.7% during the 3rd quarter. BNP Paribas Financial Markets now owns 73,272 shares of the company’s stock valued at $267,000 after purchasing an additional 69,582 shares during the last quarter. State Street Corp lifted its holdings in ChromaDex by 11.3% during the 3rd quarter. State Street Corp now owns 618,028 shares of the company’s stock valued at $2,256,000 after purchasing an additional 62,692 shares during the last quarter. Barclays PLC lifted its position in ChromaDex by 322.1% during the 3rd quarter. Barclays PLC now owns 70,072 shares of the company’s stock worth $256,000 after buying an additional 53,472 shares in the last quarter. Finally, Sargent Investment Group LLC acquired a new position in ChromaDex during the 4th quarter worth about $263,000. 15.41% of the stock is owned by institutional investors.

ChromaDex Stock Up 3.7 %

Shares of ChromaDex stock opened at $5.64 on Friday. ChromaDex Co. has a 12 month low of $1.57 and a 12 month high of $7.97. The business has a fifty day simple moving average of $5.61 and a 200 day simple moving average of $5.05. The stock has a market cap of $430.80 million, a PE ratio of 564.56 and a beta of 2.21.

Insider Buying and Selling

In related news, Director Frank L. Jaksch, Jr. sold 37,161 shares of ChromaDex stock in a transaction on Friday, December 13th. The stock was sold at an average price of $6.19, for a total transaction of $230,026.59. Following the completion of the sale, the director now directly owns 244,179 shares of the company’s stock, valued at $1,511,468.01. The trade was a 13.21 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 9.64% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on CDXC shares. Roth Mkm upped their price target on shares of ChromaDex from $6.00 to $8.00 and gave the stock a “buy” rating in a research report on Wednesday, November 6th. HC Wainwright raised their price target on ChromaDex from $6.00 to $8.00 and gave the company a “buy” rating in a report on Monday, November 4th. Finally, StockNews.com upgraded ChromaDex from a “buy” rating to a “strong-buy” rating in a report on Monday, February 24th.

ChromaDex Profile

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.